News

Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum
Q1 2025 Management View CEO Jay Duker highlighted the progress of DURAVYU, their lead program for treating wet AMD, noting ...